These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 23163663)

  • 1. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.
    Armstrong MJ; Houlihan DD; Rowe IA; Clausen WH; Elbrønd B; Gough SC; Tomlinson JW; Newsome PN
    Aliment Pharmacol Ther; 2013 Jan; 37(2):234-42. PubMed ID: 23163663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity.
    Newsome P; Francque S; Harrison S; Ratziu V; Van Gaal L; Calanna S; Hansen M; Linder M; Sanyal A
    Aliment Pharmacol Ther; 2019 Jul; 50(2):193-203. PubMed ID: 31246368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
    Jendle J; Nauck MA; Matthews DR; Frid A; Hermansen K; Düring M; Zdravkovic M; Strauss BJ; Garber AJ;
    Diabetes Obes Metab; 2009 Dec; 11(12):1163-72. PubMed ID: 19930006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
    Russell-Jones D; Vaag A; Schmitz O; Sethi BK; Lalic N; Antic S; Zdravkovic M; Ravn GM; Simó R;
    Diabetologia; 2009 Oct; 52(10):2046-55. PubMed ID: 19688338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies.
    Bode BW; Brett J; Falahati A; Pratley RE
    Am J Geriatr Pharmacother; 2011 Dec; 9(6):423-33. PubMed ID: 22055210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
    Klein DJ; Battelino T; Chatterjee DJ; Jacobsen LV; Hale PM; Arslanian S;
    Diabetes Technol Ther; 2014 Oct; 16(10):679-87. PubMed ID: 25036533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
    Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
    JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
    Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
    Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).
    Kuchay MS; Krishan S; Mishra SK; Choudhary NS; Singh MK; Wasir JS; Kaur P; Gill HK; Bano T; Farooqui KJ; Mithal A
    Diabetologia; 2020 Nov; 63(11):2434-2445. PubMed ID: 32865597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists.
    Cuthbertson DJ; Irwin A; Gardner CJ; Daousi C; Purewal T; Furlong N; Goenka N; Thomas EL; Adams VL; Pushpakom SP; Pirmohamed M; Kemp GJ
    PLoS One; 2012; 7(12):e50117. PubMed ID: 23236362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone.
    Ohki T; Isogawa A; Iwamoto M; Ohsugi M; Yoshida H; Toda N; Tagawa K; Omata M; Koike K
    ScientificWorldJournal; 2012; 2012():496453. PubMed ID: 22927782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.
    Suzuki D; Toyoda M; Kimura M; Miyauchi M; Yamamoto N; Sato H; Tanaka E; Kuriyama Y; Miyatake H; Abe M; Umezono T; Fukagawa M
    Intern Med; 2013; 52(10):1029-34. PubMed ID: 23676586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).
    Marre M; Shaw J; Brändle M; Bebakar WM; Kamaruddin NA; Strand J; Zdravkovic M; Le Thi TD; Colagiuri S;
    Diabet Med; 2009 Mar; 26(3):268-78. PubMed ID: 19317822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with Type 2 diabetes: a meta-analysis of sub-population data from seven phase III trials.
    Shomali ME; Ørsted DD; Cannon AJ
    Diabet Med; 2017 Feb; 34(2):197-203. PubMed ID: 27412701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
    Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
    Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mild renal impairment and the efficacy and safety of liraglutide.
    Davidson JA; Brett J; Falahati A; Scott D
    Endocr Pract; 2011; 17(3):345-55. PubMed ID: 21700561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
    le Roux CW; Astrup A; Fujioka K; Greenway F; Lau DCW; Van Gaal L; Ortiz RV; Wilding JPH; Skjøth TV; Manning LS; Pi-Sunyer X;
    Lancet; 2017 Apr; 389(10077):1399-1409. PubMed ID: 28237263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.
    Cusi K; Sattar N; García-Pérez LE; Pavo I; Yu M; Robertson KE; Karanikas CA; Haupt A
    Diabet Med; 2018 Oct; 35(10):1434-1439. PubMed ID: 29869810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.